Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
200M0.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1K0.0%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1K0.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$18K0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6K0.0%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemJune 30, 2026December 31, 2025
Redeemable convertible preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares and 2,601,826 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively15,784
Redeemable noncontrolling interests — Cullgen redeemable convertible preferred stock113,030
Stockholders’ equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 106,033,763 shares and 91,314,007 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively10691
Additional paid-in capital240,644172,819
Statutory reserve3,6483,098
Accumulated deficit(137,962)(112,603)
Accumulated other comprehensive income (loss)1,492(908)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s common stock?
Gyre Therapeutics, Inc. (GYRE) reported common stock of $106K in Q2 2026.
How has Gyre Therapeutics, Inc.'s common stock changed year-over-year?
Gyre Therapeutics, Inc.'s common stock increased by 16.5% year-over-year, from $91K to $106K.
What is the long-term trend for Gyre Therapeutics, Inc.'s common stock?
Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s common stock has grown at a 32.8% compound annual growth rate (CAGR), from $22K to $91K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Gyre Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude